Comprehensive genetic studies have determined a very low frequency of actionable mutations in advanced LCNEC—for example, <2% for ALK fusions in two large series: 0/43 patients (Rekhtman et al. 2016) and 1/61 patients (Akhoundova et al. 2022). The gene discussed is ALK; the disease is large cell neuroendocrine carcinoma.